• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

New standardized score identifies patients who should be treated with shorter duration dual-antiplatelet therapy

byCaitlyn HuiandDeepti Shroff Karhade
June 14, 2017
in Cardiology, Chronic Disease, Imaging and Intervention, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Standardized score suggests that prolonged dual antiplatelet therapy (DAPT) is harmful for patients with low DAPT scores.

2. Prolonged DAPT may reduce risk of ischemic events in patients with high scores receiving paclitaxel-eluting stents.

Evidence Rating Level: 2 (Good)

Study Rundown: The DAPT score is a new, standardized system of predicting which patients will benefit from prolonged DAPT. DAPT involves both aspirin and oral P2Y12 adenosine diphosphate-receptor inhibitors, and is currently recommended in guidelines as standard of care for patients with coronary artery disease undergoing percutaneous coronary intervention. Despite the evidence to support DAPT, not all patients benefit from prolonged therapy and the relationship between the DAPT score and safety of DAPT duration are currently unclear. Therefore, the authors of this study aimed to assess the efficacy and safety of prolonged DAPT based on DAPT score. In general, it was observed that prolonged DAPT is not beneficial for patients with a low DAPT score. This study has several limitations. First, while the variables were included in the DAPT score were collected prospectively, the score had to be calculated retrospectively as it was not available at the time of collection. Additionally, risk estimates were imprecise as few ischemic events occurred in general.

Click to read the study in the Annals of Internal Medicine

Relevant Reading: Antiplatelet therapy: New score for predicting bleeding risk after DAPT

In-Depth [retrospective cohort]: In this retrospective assessment of DAPT score,1970 patients undergoing percutaneous coronary intervention (PCI) were included in the study. The primary outcomes measured consisted of death, myocardial infarction, or cerebrovascular accident and were assessed at 6 versus 24 months. Safety was also assessed as type 3 or 5 bleeding, based on the Bleeding Academic Research Consortium’s definition. Generally, the primary safety outcome was higher in patients with low DAPT scores for 24 months compared to 6 months (risk difference [RD] for score ≥ 2, 0.20 percentage point [CI, -1.20 to 1.60 percentage points]; RD for score < 2, 2.58 percentage points [CI, 0.71 to 4.46 percentage points]; p = 0.046). Additionally, a greater reduction in primary efficacy outcome was observed with 24- compared to 6-month DAPT for patients with high DAPT scores. Primary efficacy of DAPT also varied by stent type. For example, prolonged DAPT with patients with high scores was effective in those that received paclitaxel-eluting stents (RD for score ≥ 2, 0.20 percentage point [CI, -1.20 to 1.60 percentage points]). In contrast, the benefit of DAPT is still unclear in patients receiving contemporary drug-eluting stents.

RELATED REPORTS

Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy

Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications

Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antiplateletcardiovascular diseaseprognosis
Previous Post

2 Minute Medicine Rewind June 12, 2017

Next Post

HbA1c overestimates mean glucose in black persons compared with whites

RelatedReports

2 Minute Medicine Rewind October 12 – 19, 2014
Cardiology

Moderate-intensity statin plus ezetimibe is non-inferior to high-intensity statin monotherapy

August 10, 2022
Rilonacept may lower pericarditis recurrence in patients with relapsing pericarditis
Cardiology

Dapagliflozin associated with reduced risk of cardiovascular and kidney outcomes irrespective of background use of cardiovascular medications

July 28, 2022
Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial
Cardiology

Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force

June 24, 2022
European data showed coffee consumption associated with lower mortality
Cardiology

Unsweetened coffee consumption is associated with reduced risk of mortality

June 21, 2022
Next Post
Pediatric DKA associated with recent acute care visits

HbA1c overestimates mean glucose in black persons compared with whites

Five risk factors linked to half of preventable cardiovascular deaths

Parenting intervention in African American youth yields lower cotinine levels

Characteristic differences between young children and adolescents who die by suicide

Inverse relationship between level of education and risk of cardiovascular disease

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Internet cognitive behavioral therapy may improve insomnia in chronic pain patients
  • Same appointment mammogram results may result in less stress for patients being screened for breast cancer
  • Increased use of pediatric CT poses significant oncogenic risk [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.